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Abstract
Background: Residual disability after stroke is substantial; 65% of patients at 6 months are unable to incorporate
the impaired upper extremity into daily activities. Task-oriented training programs are rapidly being adopted into
clinical practice. In the absence of any consensus on the essential elements or dose of task-specific training, an
urgent need exists for a well-designed trial to determine the effectiveness of a specific multidimensional task-based
program governed by a comprehensive set of evidence-based principles. The Interdisciplinary Comprehensive Arm
Rehabilitation Evaluation (ICARE) Stroke Initiative is a parallel group, three-arm, single blind, superiority randomized
controlled trial of a theoretically-defensible, upper extremity rehabilitation program provided in the outpatient
setting.
The primary objective of ICARE is to determine if there is a greater improvement in arm and hand recovery one
year after randomization in participants receiving a structured training program termed Accelerated Skill Acquisition
Program (ASAP), compared to participants receiving usual and customary therapy of an equivalent dose (DEUCC).
Two secondary objectives are to compare ASAP to a true (active monitoring only) usual and customary (UCC)
therapy group and to compare DEUCC and UCC.
Methods/design: Following baseline assessment, participants are randomized by site, stratified for stroke duration
and motor severity. 360 adults will be randomized, 14 to 106 days following ischemic or hemorrhagic stroke onset,
with mild to moderate upper extremity impairment, recruited at sites in Atlanta, Los Angeles and Washington, D.C.
The Wolf Motor Function Test (WMFT) time score is the primary outcome at 1 year post-randomization. The Stroke
Impact Scale (SIS) hand domain is a secondary outcome measure.
The design includes concealed allocation during recruitment, screening and baseline, blinded outcome assessment and
intention to treat analyses. Our primary hypothesis is that the improvement in log-transformed WMFT time will be greater
for the ASAP than the DEUCC group. This pre-planned hypothesis will be tested at a significance level of 0.05.
Discussion: ICARE will test whether ASAP is superior to the same number of hours of usual therapy. Pre-specified
secondary analyses will test whether 30 hours of usual therapy is superior to current usual and customary therapy not
controlled for dose.
Trial registration: www.ClinicalTrials.gov Identifier: NCT00871715
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Background
Of the 795,000 individuals who will experience a new or
recurrent stroke in the U.S. each year, a majority will have
considerable residual disability [1-6]. Sixty-five percent of
patients at 6 months are unable to incorporate the paretic
hand effectively into daily activities [2,7]. In turn, this de-
gree of disability contributes to a reduced quality of life
after stroke [3,7-9]. The extent of disability has been
under-represented by measures that capture only basic ac-
tivities of daily living, such as self-care, and do not extend
to activities and participation at higher levels of function-
ing that are most affected by a residual upper extremity
disability [1,10-14]. Against this background, we designed
and initiated the Interdisciplinary Comprehensive Arm
Rehabilitation Evaluation (ICARE) Stroke Initiative. Al-
though the proportion of stroke survivors who are mildly
to moderately impaired is not definitively known, conser-
vative estimates range between 5% and 30%. These are
individuals who return to the community but with signifi-
cant disability [15]. The paucity of dose-equivalent designs
in the stroke upper extremity clinical trial literature
(including the EXCITE (Extremity Constraint-Induced
Therapy Evaluation) trial) [16], highlights the necessity
and importance of this phase III RCT evidence [17,18].
The past decade has witnessed an explosion of different
therapeutic interventions intended to capitalize on the
brain’s inherent plasticity to increase adaptation to injury
and learning into old age. The upper extremity (UE) inter-
ventions with the strongest evidence, and potentially the
most immediate and cost-effective appeal for the current
healthcare environment, share a common emphasis on fo-
cused task-specific training applied with an intensity
higher than usual care [19,20]. Given this knowledge and
considering the continuing constraints placed upon the
total number of treatment hours for upper extremity re-
habilitation, determining whether a program that is based
both upon best practice and evidence-based interventions
is superior to current care becomes imperative. Moreover,
the value of such a program needs to be realistic given
prevailing practice patterns; any superiority cannot simply
be related to the amount of therapy provided. Such an
intervention would incorporate a number of dynamic and
competing processes with the following critical goals:
1) enable a balanced interaction between processes asso-
ciated with experience-dependent and injury-induced
cortical reorganization to best guide functional recovery
[21-23]; 2) attenuate the detrimental effects of maladaptive
compensatory strategies (e.g., learned non-use), often cur-
rently promoted during inpatient rehabilitation [2], that
may with time persist and become more difficult for the
patient and clinician to reverse [24]; 3) foster an early, but
not too early, aggressive approach during a more vulner-
able period both physiologically and psychologically
[21,25,26]; and 4) overcome the challenges of introducing
a principle-based, distributed, upper extremity task-specific
training program into an already dwindling acute inpatient
length of stay where UE use is frequently minimal [2,17,27].
ICARE is a randomized controlled trial (RCT) designed
to compare ASAP, an integrated set of three essential ele-
ments (skill, capacity, motivation) bundled together in a
theoretically defensible and reproducible protocol, to an
equivalent dose of usual and customary outpatient therapy.
To date, few upper extremity rehabilitation clinical trials
have included dose equivalency in the therapy application
trial design. The dose-equivalent control comparison is a
particularly appropriate alternative given that: 1) the EX-
CITE trial design and findings did not rule out the possibil-
ity that usual and customary care provided at the same
dose and intensity as constraint-induced movement therapy
(CIMT) would have been as efficacious, 2) findings from
the VECTORS (Very Early Constraint-Induced Movement
during stroke rehabilitation) trial showed that a higher in-
tensity of CIMT applied acutely after stroke was less effica-
cious, while a lower intensity of CIMT yielded comparable
results to a dose-equivalent usual therapy group, and
3) well-designed investigations of upper extremity rehabili-
tation applied in the outpatient setting that compare the ef-
fectiveness of task-specific training to that of an equivalent
dose of conventional therapy are sorely lacking [28-30] with
one recent exception [31]. Finally, the non-dose-equivalent,
observation only group (UCC) will help determine whether
ASAP or DEUCC or both are superior to current clinical
practice.
Methods/design
We will test our hypotheses by randomizing 360 partici-
pants into a three center, single blind randomized con-
trolled trial to investigate the effectiveness of a focused,
intense, evidence-based, upper extremity rehabilitation
program (ASAP) administered during the early post-
acute stroke outpatient interval. Motor and quality of life
measures of participants post-stroke randomized to ASAP
treatment will be compared to those of participants admi-
nistered an equivalent dose of usual and customary out-
patient therapy (dose-equivalent usual and customary
care, DEUCC), and an observation only usual and custom-
ary (UCC) occupational therapy control group. The pri-
mary study time point is 1 year after randomization. Our
ultimate goal is to provide evidence to optimize post-
stroke rehabilitation practice for those with mild to mod-
erate upper limb impairments and reduce disability in the
broadest sense.
All procedures conducted during this trial with human
participants are carried out in compliance with federal
and institutional ethical standards and in compliance
with the Helsinki Declaration. All research procedures
are approved by an Institutional Review Board at each of
the participating sites: University of Southern California
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Health Sciences Campus Institutional Review Board
(protocol #HS-07-00148), Emory University Institutional
Review Board (protocol #IRB00001180), MedStar Na-
tional Rehabilitation Hospital/MedStar Health Research
Institute (protocol #2007-161), Rancho Los Amigos Na-
tional Rehabilitation Center Institutional Review Board
(protocol #037), Casa Colina Centers For Rehabilitation
Institutional Review Board (protocol #HS-07-00148),
Long Beach Memorial Care Health System Institutional
Review Board (protocol #428-07), Huntington Memorial
Hospital Institutional Review Board (protocol #HMH
2007–049), and Cedars-Sinai Institutional Review Board
(protocol #Pro00012032).
Type of design
ICARE is a parallel group, three arm, single blind, phase
III, superiority, randomized, controlled trial of a principle-
based upper extremity training program provided in the
outpatient setting after the acute hospitalization phase.
Once discharged from an inpatient or acute setting and
following baseline assessment, participants are randomized,
no earlier than 14 days and no later than 106 days after
stroke onset, to one of three intervention groups: ASAP,
DEUCC or UCC. The primary outcome, collected at 1 year
post-randomization, is the log WMFT time score. The sec-
ondary outcomes are the SIS hand domain subscale and
the full SIS scores. To prevent unintended crossover,
details of the ASAP protocol are currently embargoed;
therapists who provide ASAP sign a confidentiality and
nondisclosure agreement and do not provide UCC or
DEUCC treatments. Outcome assessors are blinded to
treatment group. The study flow is illustrated in Figure 1.
Study enrollment
Each center (University of Southern California, Emory
University, and National Rehabilitation Hospital/George-
town University) is expected to randomize 120 indivi-
duals. To confirm eligibility, pre-screening, screening, a
brief medical examination and baseline evaluation are
administered at one of the seven ICARE clinical sites.
Eligible individuals who have provided informed consent
are randomized following a baseline evaluation. Enroll-
ment is defined by having signed a Study Informed
Consent. The purpose and timing of events from pre-
screening to randomization are summarized in Table 1.















Study Informed Consent &
Consent to be Videotaped
Figure 1 Study flow from referral to follow-up. The primary endpoint is 1 year after randomization.
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Accessing and collecting personal health information
In ICARE, both HIPAA Waiver and Authorization are
employed in a two-tiered process: a) pre-screening; and
b) screening, to assure privacy protection while minimizing
prospective participant burden. Prospective participants are
first identified through a review of admissions to the in-
patient rehabilitation and acute medical units affiliated with
ICARE clinical sites or by direct referral. Stroke diagnosis is
initially confirmed by ICD-9 code, census review with the
treating stroke teams, or the direct referral source. For
those individuals with a confirmed stroke diagnosis, a chart
review for non-modifiable exclusionary criteria (e.g. age,
stroke characteristics, co-morbidities) is performed. Indivi-
duals passing the express chart screen are approached for
the initial in person consented screening phase.
Informed consent
ICARE uses a two-step consenting process; participants are
asked to consent to a screen, and if qualified, a second con-
sent is obtained for full study participation. Once a poten-
tial participant has been determined to qualify for
screening, s/he is asked to sign the HIPAA Authorization
and Screening Informed Consent to participate in a brief
and detailed screen to determine study eligibility.
Screening process
The pre-screening and screening processes are completed
so that randomization occurs no later than 106 days post-
stroke onset according to protocol. The pre-screen, or
Express Chart Screen (ECS), is a chart review of non-
modifiable eligibility criteria (Tables 1 & 2). The screening
process occurs in two phases: 1) Brief Clinical Screen (BCS)
and 2) Detailed Clinical Screen (DCS). Candidates who pass
the BCS are followed by the Clinical Site Coordinator
(CSC), and administered the DCS at an individually deter-
mined time, adjusted to maximize the candidate’s potential
for eligibility. Candidates who pass the DCS are offered the
study informed consent and videotape consent. Enrollment
commences with a signed Study Informed Consent. Upon
receipt of these consents, the participant is scheduled for a
Brief Medical Exam (BME) and Baseline Evaluation to be
performed just prior to randomization. Eligibility criteria,
pre-identified as likely to change during the screening
phase (i.e., motor function, medical stability, and desire to
participate), are confirmed at the BME and Baseline
Evaluation.
If a participant fails a specific screening criterion, he/she
is deemed ineligible for the study. Initial failure of certain
criteria that are likely to change during this dynamic period
Table 1 Pre-screening to randomization flow with purpose and time interval
STUDY PHASE EVENT PURPOSE TIME INTERVAL
PRE-SCREENING Express Chart Screen (ECS) Chart review for excludable non-modifiable criteria is performed
under IRB-approved HIPAA waiver.
Before 106th day post-stroke
SCREENING HIPAA Authorization &
Screening Informed
Consent (IFC)
Prospective Participants (PP’s) who pass Pre-Screen are introduced
to the study. A signed HIPAA Authorization & Screening IFC are
required to proceed.
Brief Clinical Screen (BCS) An initial brief screen is completed to ensure sufficient motor and
cognitive recovery and pre-morbid function for eligibility. If




If BCS is passed, a detailed clinical screen for eligibility is
administered. PP’s Primary Care Physician is notified if DCS is




Study IFC & Consent To
Be Videotaped
PP’s who pass DSC are informed about the study in greater detail.
A signed Study IFC and Consent to be Videotaped define
enrollment and are required to proceed.
BASELINE Brief Medical Exam At
Baseline (BME)
Medical exam releases PP to participate in trial. Rules out interim
neurologic event and serves as re-check for severe depressive
symptoms. Opportunity for SPI to establish blood pressure, heart
rate, weight-bearing and other medical parameters for safe
participation.
Baseline Evaluation Confirms UE motor eligibility. Establishes baseline measures for
testing hypotheses.
Within 72 hours post-BME1
and between 14–106 days
post-stroke.
RANDOMIZATION Group Assignment Treatment group assignment ≤ 48 hours post-Baseline and
between 14–106 days post-
stroke
1Ideally the Baseline Evaluation will occur within 72 hours post-BME (Brief Medical Exam). If more than 72 hours has transpired, participant must be re-cleared of
an interceding neurologic event. PP = Prospective participant; ECS = Express Chart Screen; BCS = Brief Clinical Screen; IFC = Informed Consent; DCS = Detailed
Clinical Screen; SPI = Site Physician Investigator.
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Table 2 Eligibility criteria
INCLUSION
1. Ischemic or hemorrhagic stroke (subdural and epidural effusions permitted) within the previous 106 days
2. Hemiparesis (weakness) in arm or hand
3. Some active finger extension movement by close of enrollment window
4. Age 21+
5. Able to communicate in English
6. Willing to attend outpatient therapy and all study evaluations
EXCLUSION (truncated list)
Neurologic symptoms or conditions
1. Traumatic or non-vascular brain injury, subarachnoid hemorrhage, AV malformation, acute subdural or epidural hematoma
2. Neurologic condition that may affect motor response (e.g. Parkinson’s, ALS, MS)
3. Presence of ataxia per NIHSS [32] and evidence of cerebellar or brainstem lesion
4. Absent upper extremity sensation per NIHSS
5. Neglect asymmetry > 3 per Mesulam Unstructured [33]
6. A second stroke within the last 72 hours cannot be ruled out before the brief medical exam (BME)
Physical attributes affecting movement or function
1. Total UE Fugl-Meyer score <19 or >58, or = 0 for finger mass extension/grasp release hand score
2. UE pain that substantially interferes with ADL’s
3. Maximum assistance required for mobility
4. Passive ROM limitation of the hemiparetic upper extremity that prevents functional use of limb/hand, including any of the following:
1. Shoulder: flexion <90°, abduction <90°, external rotation <45°
2. Elbow/Forearm: extension <−20°, supination or pronation < 45° from neutral
3. Wrist/Finger: flexion or extension <0°, MCP or IP extension <30°
Pre-morbid status
1. Head trauma requiring > 48 hours of hospitalization within past 12 mos.
2. Psychiatric illness requiring hospitalization within past 24 mos.
3. Arm or hand injury limiting use prior to stroke
4. Amputation of all fingers or thumb of affected hand
5. Pre-morbid motor impairment of the contralateral upper extremity of neurologic origin
6. Barthel Index [10] < 95
Medication, Drug and/or Alcohol
1. Active or recent drug treatment for dementia
2. Treated with Botox in affected arm within last 3 months
3. Toxicology screen positive for illegal substances or reported use within the past 3 years
4. Reported alcohol use per CAGE or treatment for withdrawal since index stroke
Cognition and Participation
1. Enrollment in a conflicting study
2. Expected inability to participate in study due to illness, social, or geographic reasons
3. Unable to follow a 2-step command per NIHSS
4. < 2 on the Mini-Cog [34] with an abnormal Clock Draw Test (CDT) [35] or score = 0
5. PHQ-9 total score between 10 and 19 without management plan or score >19
6. Judged medically unstable and/or unable to participate by primary physician or SPI
Other
1.
Received > 6 hours of Outpatient Occupational Therapy (OT) since stroke (Home Health and OT Evaluation do not count toward 6 hour
maximum)
2. Clinician’s best judgment (multiple factors in combination): The SPI and CSC concur that the PP is NOT a candidate for randomization
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of recovery, such as motor function, sensation, or depres-
sive symptoms, does not necessarily lead to ineligibility.
The Clinical Site Leadership team (CSC and Site Physician
Investigator (SPI)) has the option of withholding a decision
of disqualification in lieu of re-screening during the eligible
post-stroke period. If all eligibility criteria are passed at the
Baseline Evaluation, the participant is randomized. Essential
details of the ECS, BCS, DCS, BME and Baseline Evaluation
prior to randomization are detailed in Table 1 along with
the time interval within which these events are performed.
Inclusion and exclusion criteria
Stroke diagnosis
Participants are adults with diagnosis of ischemic stroke
or intraparenchymal hemorrhagic stroke. CT or MRI
scans are used to confirm stroke diagnosis. If a scan is not
available, the diagnosis is confirmed by clinical criteria.




There are four evaluation points in ICARE: baseline, com-
pletion of intervention, and 6 months and 1 year after
randomization (Figure 1). The primary time point at 1 year
is used to test the primary and secondary hypotheses using
the analysis plan described herein.
The log-transformed WMFT time score at the 1 year
endpoint is the primary outcome measure for the trial and
the basis of a priori sample size and sensitivity estimates.
The SIS hand domain and full SIS constitute the secondary
outcome measures. The WMFT and SIS are described in
detail below. A full list of assessments is included in Table 3,
which describes the timing for data acquisition by each in-
strument including the WMFT and SIS. The full battery of
assessments is designed to provide information about
muscle strength, cognition, digit sensation-perception,
functional ability, depression, self-efficacy, life satisfaction,
reintegration, and subjective quality of life. These are listed
in the Additional file 1 and arranged roughly into categories
using the International Classification of Functioning and
Disability Framework [36] (ICF).
Trained licensed occupational or physical therapists
blinded to group assignment (Blinded evaluators, BE) and
certified for administration, perform all evaluations. The
primary outcome assessment is filmed using a digital video
camera according to detailed procedures outlined in the
Manual of Procedures (MOP). Identical computer, digital
video camera, editing, compression and conversion soft-
ware are standard equipment that were issued to each
ICARE site during the start-up phase. A FTPS (File Trans-
fer Protocol Secure) server is maintained to enable digital
video review and standardization and data file transfer
across sites and to the trial’s administrative team.
Wolf motor function test (WMFT)
The WMFT is a laboratory-based functional assessment of
the arm and hand [62]. The instrument includes 15 mea-
sures of speed (timed tasks), 2 measures of strength (arm,
grip), and 15 measures of movement quality using the
Functional Ability Scale (FAS) of the upper extremity [63].
The FAS movement quality score is determined from video
review by a panel of raters blinded to treatment group and
assessment time point. Items include a hierarchically
arranged set of functional movements of the shoulder,
elbow and hand that progress from proximal movements
to distal hand tasks including grasp control and manipula-
tion. The WMFT has been shown to be both reliable and
valid in the stroke population [64,65]. It has been used pre-
viously, in numerous studies including the EXCITE and
VECTORS trials.
Stroke impact scale (SIS)
The Stroke Impact Scale (SIS) 3.0 is a well-established 59-
item interviewer-administered assessment of health-related
quality of life for individuals after stroke [66,67]. The SIS
captures 8 domains of function organized into subscales as
well as an overall measure of perceived recovery from
stroke. Both the full SIS 3.0 (ICF Participation level) and
the hand function subscale (ICF Activity level) are used in
ICARE as secondary outcome measures. The hand function
subscale requires participants to indicate the difficulty
experienced over the past 2 weeks with 5 activities involv-
ing the paretic hand, including: carrying heavy objects,
turning a doorknob, opening a can or jar, tying a shoelace,
and picking up a small coin.
Other assessments
Monthly follow-up interviews
Within 30 days of randomization, the recruiting site team
initiates monthly telephone interviews with each participant
to ascertain information about health status, healthcare
utilization, medications, other therapies, and adverse
events.
Post-intervention interview
A multiple question survey interview is administered by a
non-treating, unblinded member of the recruiting team
upon completion of the intervention phase. At the post-
intervention evaluation, each participant is asked a set of
questions to assess the extent to which critical components
of the investigational intervention (e.g. impairment mitiga-
tion, session intensity, participant chosen tasks, therapist-
participant collaboration) were incorporated into each
assigned therapy group [68].
Exit interview
At the final 1 year evaluation, participants complete an-
other set of questions regarding activity since the end of the
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intervention phase. Participants are also asked to report the
perceived value of the intervention and study participation.
Usual care evaluation and treatment records
Receipt of usual and customary care, defined as out-
patient occupational therapy (OT), is monitored and
recorded from stroke onset to study endpoint. No more
than six hours of outpatient occupational therapy treat-
ment, excluding an OT initial evaluation, is permitted
prior to randomization. Usual care in treatment hours is
recorded at the time of randomization. Once rando-
mized and through the end of the intervention observa-
tion window (16 weeks post-randomization), usual care
is recorded at an individual session level for all treat-
ment groups. Data include: 1) Date, 2) Length of treat-
ment session in minutes, 3) Content, using CPTW codes,
4) Payer, 5) Location (at an ICARE site (on-site) or other
therapy locations (off-site)), and 6) Change in (OT) pre-
scriptions. Additional data collected include: initial pre-
scription, all missed appointments and reason for
Table 3 Baseline and follow-up assessments for each participant at each time point






Patient Health Questionnaire, (PHQ-9) [37,38] X5 X X X
NIH Stroke Scale (NIHSS) [32,39-41] X5 X X X
WMFT, 15 timed items X X X X
WMFT, 2 strength items X X X X
WMFT Functional Ability Scale, 15 items (WMFT- FAS)
[42,43]
X X X X
Stroke Impact Scale (SIS) X X X X
Cognitive Battery – 5 items X X
•




D-KEFS Verbal Fluency Test[45]
X X
•






Color Trails 1 & 2 [47,48]
X X
Upper Extremity Fugl-Meyer, Motor (UEFM) [49,50] X X X X
Satisfaction with Life Scale (SWLS)[51-53] X X X X
Arm Muscle Torque Test [54] X X X X
AsTex Sensory Index [55] X X X X
Motor Activity Log, 28 item (MAL-28)[56] X X X
EQ5D [57] X X X X
Confidence in Arm & Hand Measure (CAHM) X X X X
Reintegration to Normal Living Index (RNLI) [58,59] X X X X
Single-Item Quality of Life Measure (SQOL) [60,61] X X X X
Physiologic Measures X X X X
Monthly Telephone Follow-up5 X X X
Post-Intervention Exit Interview5 X
Final Study Exit Interview5 X
Unless otherwise specified, assessments are administered and scored by standardized BE’s.
1Randomization occurs after baseline and between 14–106 days post stroke; thus participant and all study personnel are blinded to treatment group assignment
at the baseline evaluation.
2Post-Intervention Evaluation occurs between 16–20 weeks post-randomization.
36-month Post-Randomization Evaluation occurs between 24–28 weeks post-randomization.
412-month Post-Randomization Evaluation occurs between 50–64 weeks post-randomization.
5Items at given time points are measured by local site team personnel and not by BE’s.
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absence, discharge and discharge reason. From these
data, usual care dose, therapy content, attendance beha-
viors and reimbursement mechanisms can be used for
secondary analyses. For therapy occurring off-site, all
post-stroke outpatient OT records are procured with a
signed HIPAA authorization. For therapy on-site, the
Study Informed Consent and HIPAA authorization
signed at screening permit internal access to these
records. From the outpatient therapy records, the usual
care data are gleaned during the intervention observa-
tion window. When a participant is randomized, he or
she is provided with a monthly calendar up to the study
endpoint and instructions to record all therapies
attended, noting the date, time spent in therapy and type
of therapy. These calendars are reviewed monthly during
the telephone interview with the participant and provide
the data collected regarding ancillary therapy utilization
as well as outpatient OT received outside of the inter-
vention observation window.
Medication information
Data about medication prescription and usage are collected
during pre-screening, screening, prior to baseline and at
monthly intervals post-randomization. Prior to baseline, re-
ceipt of tPA (if known) is recorded and all prescribed medi-
cations are recorded by name. A participant-specific
medication list is developed at the time of the Baseline as-
sessment. Monthly, this list is revisited with the participant
and updated accordingly. New medications are added at
this time and data regarding discontinued medications are
recorded. These data are intended to provide supplemental
information about the medical and pharmacologic manage-
ment of the ICARE sample.
Standardization of assessments
All clinical research blinded evaluators (BE’s) must
complete an initial certification (standardization) process
for the WMFT and SIS, and maintain re-certification at
least every 6 months, thereafter. A 3-day training work-
shop was conducted during the start-up phase, serving
to introduce the BE’s to the standardized test protocols.
Updated training materials include: printed manuals of
test administration and scoring instructions; online video
demonstration; peer review; practice with volunteers
who have had a stroke; monthly training meetings; and
an online discussion board. Certification is granted for
performance of at least 90% mastery. The certifying ther-
apist views a digital recording of test administration and
scoring by the therapist seeking certification along with all
assessment-specific study documentation; detailed verbal
and written feedback are provided. All study personnel
administering the National Institutes of Health Stroke
Scale (NIHSS) [32,39,40] must obtain certification of stan-
dardized competency.
WMFT FAS rater panel
A panel of 3 experienced therapists provide FAS ratings
for the WMFT. Inter-rater reliability is refined via telecon-
ferences. The Data Management and Analysis Center
(DMAC) convert and compress the site submitted edited
digital WMFT test administration. Media stream access is
provided to the members of the rater panel through the se-
cure ICARE database website, thereby enabling remote
viewing and scoring capability. Intra-rater reliability and
inter-rater reliability were initially assessed using a sample
of 8 videotaped WMFT test administrations procured from
a database of previous studies. Raters rated each video at
that time and after 1 month. A web/teleconference followed
to review and discuss discrepant individual item ratings.
This resulted in further refinement of the scoring guide-
lines. Two additional test-retest iterations were completed,
each time with a set of 21 filmed ICARE WMFT test
administrations. These were analyzed using weighted
Kappa statistics, Spearman correlation coefficients and
Bland-Altman plotting to determine points of disagree-
ment. Currently, each of the 3 panel members rate each
video independently, to yield 3 independent ratings per
video. Specific instances of item score disagreement are
identified by the DMAC for review and discussion by the
panel before adjudication by majority vote. The WMFT
FAS Panel meets via tele-conference monthly to view and
rate a new video as a group.
Randomization method
A stratified block randomization schema is used for each
site to balance randomization assignment by motor severity
and time from stroke onset. Participants are stratified using
an ordered set of variables defined by: 1) baseline motor
impairment using the Fugl-Meyer Upper Extremity motor
score [49,69,70] (more impaired ≤ 35, less impaired ≥ 36,
eligible range 19–58); and 2) days from stroke onset (early
≤ 59 days and late 60+ days, eligible range 14–106). No
a priori assumptions are made about there being balance
across stratification factors. Randomization assignment is
obtained through the secure web-based data entry system,
which confirms that all prerequisites have been completed
before informing the CSC of the assignment. Each CSC
maintains a randomization log at the site, and the DMAC
maintains the master list for the trial. The balance of the
group assignment is monitored weekly by the DMAC, and
reported to the DSMB quarterly, with treatment group
coded to maintain blinding.
Interventions
Accelerated skill acquisition program
The Accelerated Skill Acquisition Program (ASAP) is a fully
defined, principle-based protocol that integrates three fun-
damental elements including: skill acquisition through
task-specific practice, impairment mitigation to increase
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capacity, and motivational enhancements to build self-
confidence (Figure 2). ASAP is grounded in the evidence-
based expectation that effective rehabilitation of the paretic
upper extremity is achievable and based upon the provision
of challenging, intensive, and meaningful task practice for
motor skill acquisition, mitigation of associated linchpin
impairments and dysfunctions of movement, and the confi-
dence to integrate use of emerging skills into daily life activ-
ities [2,19,20,71,72].
The ASAP structured protocol includes an initial evalu-
ation and orientation session (Session A) and 30 1-hour vis-
its of an individualized practice program focused on
function of the arm and hand most affected by the stroke.
This integrated and evidence-based intervention for upper
extremity recovery arose from diverse but converging, com-
plementary, and interdisciplinary literatures of basic and
applied science as well as recent translational and stroke
clinical trial research of upper extremity recovery. Unique
aspects include the structured framework by which
intensity and progression of practice is managed and which
fosters participant skills and confidence through therapist-
patient collaboration. Participants randomized to ASAP are
given a customized package of therapy that includes chal-
lenging, intensive, and meaningful practice of activities
related to participant chosen real-world tasks (e.g., carrying
groceries, handwriting) that engage the arm most affected
by the stroke. Participants are offered a mitt to wear on the
less affected hand during the time outside of therapy to
promote use of the weaker arm and hand; however, the par-
ticipant is not required to use the mitt if so chosen. Outside
of therapy specific assignments (i.e., Action Plans) are given
to encourage self-managed, confident, safe, and effective
arm use at home and in the community.
Table 4 summarizes the eight evidence-based, non-
exclusive (over-lapping) operating principles that are
currently used to guide ASAP intervention sessions: 1)
ensure challenging and meaningful practice [20,73-76],
2) address important mutable impairments through
task-breakdown [77-80], 3) enhance motor capacity
through overload and specificity [81,82], 4) preserve
natural goal-directedness in movement organization
[83,84], 5) try to avoid artificial task breakdown when
engaging in task-specific practice [85], 6) assure active
patient involvement and opportunities for self-direction
[86,87], 7) balance immediate and future needs for effi-
cient motor skill and capacity enhancement with the
development of confidence and self-management skills
[88,89] and 8) drive task-specific self-confidence (self-
efficacy) high through performance accomplishments
[90,91]. Together, these principles are designed to
emphasize and drive the development of skilled move-
ment performance.
ASAP protocol parameters
The program begins with an orientation and evaluation
session to accomplish the following 10 goals: 1) prepare
the collaborative ‘real-world’ task list to be used during
training; it includes 6 tasks the patient most wants
to perform with at least two bimanual activities, two
strength-dependent activities including the most affected
arm, and two activities requiring dexterity of the most
affected hand, 2) designate a priority or benchmark task
from the collaborative task list, 3) determine fundamen-
tal impairments and the priority-task challenge threshold
or movement breakdown point(s), 4) prepare a collab-
orative schedule for the first day of training, 5) orient
the participant to the mitt and its function including
safety precautions, 6) identify appropriate conditions for
mitt wearing and not wearing, 7) orient the participant to a
recurring brief self-efficacy question, 8) orient the partici-
pant to out-of-lab action plans, 9) orient the participant to
their collaborative role with the trainer and 10) obtain the
participant’s agreement to be a collaborative partner. The
orientation and evaluation Session A may last up to two full
hours.
Figure 2 Conceptual model of the Accelerated Skill Acquisition
Program (ASAP). The conceptual model reflects ASAP’s intersecting
emphases on skill acquisition, capacity building (impairment
mitigation), and motivational enhancement. Challenging movement
tasks are used as vehicles to address neurorehabilitation and
recovery.
Table 4 ASAP’s eight overlapping operating principles
Principle
1 Ensure challenging and meaningful practice
2 Address important (interfering) changeable impairments
3 Enhance motor capacity through overload and specificity
4 Preserve natural goal-directedness in movement organization
5 Avoid artificial task breakdowns when possible
6 Assure active patient involvement and opportunities for self-direction
7 Balance immediate and future needs
8 Drive task-specific self-confidence high through performance
accomplishments
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Training sessions are to be 1 hour per day, 3 times per
week for a total of 30 hours, with rest breaks allowed to
maximize engaged time-on-task. Following a debriefing of
the previously assigned Action Plan and the acquisition of
several physiologic measures (i.e., BP, heart rate, pain,
muscle soreness), each regular training session begins with
a collaborative ordering of the real-world tasks identified
during Session A (orientation and evaluation). The real-
world tasks may change as interests and goals evolve over
the 30 sessions, however the priority task may not change
for benchmarking purposes. Task and movement analysis
are done for each real-world task to determine the key
movement dysfunctions or impairments. The goal of inter-
vention training is to focus attention and effort directly on
the problematic area (i.e. dysfunction, impairment) to facili-
tate skill acquisition without simply providing a compensa-
tory strategy as an easy and quick fix to the problem.
Classic exercise-overload principles (e.g. intensity, period-
icity) are used to drive progression and build motor
capacity (e.g., muscular strength and endurance, coordin-
ation). Practice activities within the three categories of real-
world functional tasks (i.e., strength, dexterity, bimanual) are
selected based on patient task preferences. Training is col-
laborative and interactive with the participant providing
problem identification as feasible (e.g., “What is the limiting
factor when you perform that task?”) and solutions through
self-assessment and trainer feedback/suggestions. Confi-
dence building and empowerment are embedded in the
training and education during each session. Task-specific
(i.e., priority task) self-efficacy assessment is performed 4
times throughout the 30 sessions using a Brief Self-Efficacy
Rating Scale. The participant is asked to provide a number
between 0 and 10 in response to the question: “How
confident are you that you can (fill in specific priority task
activity)?” The confidence rating is followed by a question
asking, “What can we do this week to increase your capabil-
ities and raise your confidence?” As the participant gains
insight and develops self-assessment and management skills,
the response to the follow-up question is expected to be-
come more insightful and rich in self-knowledge and ways
to drive challenge and improvement. One strategy for build-
ing capacity is to perform inter-session ‘Action Plans’ or out
of clinic activities. All 30 sessions have associated Action
Plans including some with handouts that provide back-
ground information related to ASAP principles and evi-
dence. Table 5 lists the knowledge-based handouts
provided to participants and the planned distribution order
across the 30 sessions. Individual participant-specific Action
Plans are also generated and used throughout the 30 ses-
sions. These Action Plans encourage specific practice in the
home or community settings. Examples include finding a
challenging task involving food preparation or eating or
reading an education handout about motor recovery. At
the beginning of each session, participants are asked to
report on the effectiveness of their Action Plan activities on
the next day of training. The therapist also rates the partici-
pant’s engagement in the Action Plan on a scale from 1 =
no effort/did not attempt, 2 = some effort, and 3 = great ef-
fort/engagement, apparently practiced diligently.
Figure 3 illustrates the clinic environment and two exam-
ples of tasks selected by participants to practice during
ASAP sessions. To prevent cross-contamination between
study groups, further details of the investigational interven-
tion as outlined in the ASAP MOP have been embargoed
until study completion.
Standardization for the ASAP protocol
To ensure data quality and consistent administration of
the intervention among all ASAP therapists, a staged
standardization process (Phase 1 and 2, Phase 3 and Re-
certification) was developed. At each stage, an expert re-
viewer (experienced members of the ICARE Investigative
team) assesses the digital video footage accompanying
documentation for therapist mastery of each ASAP
principle implemented during a 1 hr session. Phase 1 and
2 standardizations must be attained working with a volun-
teer with stroke before a therapist may initiate therapy
with a randomized participant in the ICARE trial. Once
Phase 1 and 2 standardizations have been attained, the
therapist may begin working with an ASAP-randomized
participant to complete Phase 3 standardization. After
Phase 3 standardization is acquired, the therapist must re-
certify according to the schedule directed by the reviewer.
If in the worst case scenario, a therapist fails to demon-
strate ASAP treatment fidelity at Phase 3 certification or
recertification thereafter, all post-randomization data
accrued for a participant seen by that therapist will be
designated unusable for outcome analysis.
The Phase 1 and 2 standardization processes include
demonstration of mastery in the following three task areas:
1) administration of the Brief Self-Efficacy Question; 2) de-
termination of the challenge threshold and fundamental
movement problem for two arm and hand activities, and
3) determination of appropriate task practice intensity and
activity/task progression. Additional mastered elements for
Phase 1 and 2 include: generalized ASAP protocol aware-
ness via a knowledge test and therapist self-assessment of
at least 90% mastery. Phase 3 standardization is attained
via demonstrated mastery of the ASAP protocol through
Table 5 List of standard action plans with handouts
1. Using the soft mitt on the better hand
2. Preventing arm and hand injuries while training
3. Family and friend support
4. Helpful thoughts for performing challenging activities in public
5. Getting the most learning for your efforts (Motor learning Part I)
6. Turning science into skill (Motor learning Part II)
Winstein et al. BMC Neurology 2013, 13:5 Page 10 of 19
http://www.biomedcentral.com/1471-2377/13/5
review of the 1st and 20th treatment sessions administered
to the new therapist’s first ASAP randomized participant.
Recertification is maintained through demonstration of
continued mastery, on a target schedule of approximately
every 6 months. During the trial start-up period, a 3-day
training workshop was held for all ASAP therapists to at-
tain Phase 1 standardization. Intervention therapists in all
stages of standardization and the protocol developers facili-
tate ongoing training via monthly ASAP therapist telecon-
ferences with video and literature review, individual
conferencing, an on-line discussion board, and site visits for
digital video review and discussion of ASAP principles and
clinical experiences.
Usual and customary care (UCC)
The UCC group receives Outpatient Occupational Therapy
for the upper extremity as determined by each participant’s
individual occupational therapist, based upon usual and
customary practice standards. In accordance with those
practices, the participant attends a standard Occupational
Therapy evaluation session prior to initiating intervention
sessions (treatment). The number of visits and frequency
(dose) for the intervention is determined per the therapy
prescription generated at the evaluation, site-specific usual
and customary practices, and payer guidelines (e.g. private
insurance, HMO, Medicare). The evaluation may have oc-
curred prior to randomization. The dose may be modified
per usual and customary practices as the intervention
ensues. The treating therapist(s) documents each session
per the treating facility’s protocol and documentation meth-
ods. The CSC of the clinic that randomized the participant
is responsible for procuring the evaluation and treatment
records and gleaning the necessary information for ICARE
using standardized forms. Vital signs, as well as any symp-
toms of fatigue or stress are monitored during each session
in accordance with usual and customary standard practice.
Dose-equivalent usual and customary care (DEUCC)
The DEUCC group initially receives Outpatient Occupa-
tional Therapy for the upper extremity as determined by
each participant’s individual therapist, based upon usual
and customary practice standards in a manner identical
to the previously described UCC group with respect to
content. Differentiating this group from UCC is its dose-
equivalency with the ASAP group; each receives 30 hours
of distributed treatment. Prior to initiating treatment
(intervention) and in accordance with usual and custom-
ary practices, the participant receives a standard Occu-
pational Therapy evaluation, where a recommended
number of visits and frequency (dose) are determined, in
accordance with site-specific usual care practices. This
evaluation may have occurred prior to randomization.
Immediately following the initial evaluation, the therap-
ist and patient are notified of group assignment and 30
sessions are scheduled. According to protocol, if more
than 30 treatment sessions are scheduled, the CSC will
indicate that the treatment window is closed and a post-
test will be scheduled. Provision of further treatment is
documented via the monthly telephone interviews.
Documentation and data are collected in a manner iden-
tical to that for the UCC group.
Dose of therapy (ASAP and DEUCC)
Thirty hours of training was chosen for the ASAP proto-
col because this dosage fell within the range of previous
rehabilitation intervention trials that were shown to be
effective in the post-acute outpatient setting. A training
schedule of 30 hours of treatment, ideally distributed
into 1 hour sessions, 3 days per week over 10 weeks is
the anticipated experimental frequency for both the
DEUCC and the ASAP groups. Both interventions vary
in content and structure only. Pilot data from a multi-
site outpatient survey conducted prior to initiating
Figure 3 Examples of two participant-selected tasks. These photographs depict a participant engaged in two sensorimotor tasks, each
addressing different motor impairments and movement skills. The study participant selected these two tasks during her ASAP sessions for
practice.
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ICARE suggested that 30 hours of training would be higher
than that commonly prescribed in the outpatient post-
acute setting, and the 1 hour session length was designed
to afford practicality and allow patients to participate in
other concurrent therapy services (e.g., physical therapy
and speech therapy). Those randomized to DEUCC or
ASAP are expected to receive at least 90% (≥ 27 hours) of
the 30 scheduled hours between 10 to 16 weeks post-
randomization to be considered adherent to the dosing
protocol. Therapy may extend up to 16 weeks to compen-
sate for delays in initiating treatment post-randomization,
missed sessions due to illness or other unavoidable
absences. Precise tracking of therapy dose is maintained on
all participants including: frequency and duration of indi-
vidual treatment sessions, duration of total treatment ses-
sions, and number of missed and canceled appointments.
Additionally, for the UCC and DEUCC groups, initial OT
prescription, prescription change, treatment venue and
change in treatment venue are documented.
Statistical analysis
Sample size and participant accrual
Sample size estimates were computed for the primary a
priori aim of detecting a clinically relevant difference in
log-transformed WMFT time score between ASAP and
DEUCC at 1 year follow up with α = 0.05. With the pro-
posed total sample of 360, we would have sufficient
power to detect a moderate difference in treatment
effect of Δ = 0.40 for an attrition rate of 17%, and Δ =
0.42 for an attrition rate of 25% using a two-group
2-sided t-test with a type I error of 0.05 and 80% power.
The EXCITE trial showed treatment effect sizes of 0.50
and 0.63 for the high and low functioning groups, re-
spectively. For the small sample phase II VECTORS
study, a similar analysis showed a treatment effect size
of 0.20. Given the outpatient timing of ICARE, a less
dynamic period of change than VECTORS, we expect to
have sufficient power to detect the effect size in log
WMFT time score. We also should have sufficient power
to detect a difference in the proportion of participants
who change ≥ 25 points on the normalized SIS at 1 year
using a χ2 statistic. The minimal success rate difference
that can be detected with 80% power ranges from 13.5-
20% (with 17% attrition) to 14.0-21% (with 25% attrition);
the variation in the estimates reflects potential variation in
improvement in the DEUCC group. To achieve this re-
cruitment goal (N = 360) in 40 months, each of the three
centers aims to randomize 3 participants per month.
Specific aims
Primary Aim and hypotheses
Specific Aim 1 To compare the efficacy of a fully-
defined, evidence-based and theoretically defensible
therapy program (ASAP) and an equivalent dose of
usual and customary Occupational Therapy (DEUCC)
initiated within the earliest post-acute outpatient inter-
val (14–106 days post stroke) for significant gains in the
primary outcome of paretic upper extremity function
1 year after randomization.
Hypothesis 1 At 1 year post randomization, the time
score from the WMFT will be significantly smaller (faster)
after ASAP than usual and customary occupational therapy
care (DEUCC), controlled for dose.
Secondary hypothesis for SA 1 At 1 year post
randomization, the proportion of patients with success-
ful outcomes measured by the Stroke Impact Scale
(SIS) hand domain and full SIS will be greater after
ASAP than DEUCC, controlled for dose.
Secondary Aim and hypotheses
Specific Aim 2A To compare the efficacy of a fully-
defined, evidence-based and theoretically defensible therapy
program (ASAP) to that of an observation only usual and
customary (UCC) occupational therapy program initiated
within the earliest post acute outpatient interval
(14–106 days post stroke) for significant gains in the
primary outcome of paretic upper extremity function
1 year after randomization.
Hypothesis for SA 2 At 1 year post randomization, the
time score from the WMFT will be significantly smaller
(faster) after ASAP than UCC, uncontrolled for dose.
Secondary hypothesis for SA 2A At 1 year post
randomization, the proportion of patients with successful
outcomes measured by the SIS hand and full SIS will be
greater after ASAP than UCC, uncontrolled for dose.
Specific Aim 2B To compare the efficacy of one dose-
equivalent usual and customary outpatient occupational
therapy program (DEUCC) to an observation only, usual
and customary outpatient occupational therapy (UCC) pro-
gram initiated within the earliest post-acute outpatient
interval (14–106 days post stroke) for significant gains in
the primary outcome of paretic upper extremity function
1 year after randomization.
Hypothesis for SA 2B At 1 year post randomization, the
time score from the WMFT will be significantly smaller
(faster) after DEUCC than UCC, uncontrolled for dose.
Secondary hypothesis for SA 2B At 1 year post
randomization, the proportion of patients with successful
outcomes measured by the SIS hand domain and full SIS
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Descriptive statistics of demographics, baseline character-
istics, and distributions will be performed for the total
sample and for each group. Group comparisons will be
made to examine whether any of these variables need to
be accounted for in further analysis due to an imbalance
across groups. Continuous variables will be compared
using ANOVA for normally distributed variables to test
for mean differences, and Wilcoxon rank sum test will be
used for non-normally distributed variables to test for me-
dian differences. χ2 or Fisher’s exact test will be used for
categorical variables to test for frequency differences. Par-
ticipant characteristics that differ at baseline will be
included as covariates in the analysis of the primary and
secondary outcomes.
Analysis plan
This trial addresses two different questions separated by
primary aim and secondary aim: 1) Is ASAP superior to
DEUCC (primary aim)?, and 2) Is ASAP or DEUCC super-
ior to UCC, (secondary aim) For all analyses, assumptions
required for the data distribution (e.g., normal distribution)
will be assessed. Any transformations of data or alternative
methods necessary to analyze the data will be determined
by examining the structure of the data. All analyses will be
performed in accord with the intent-to-treat (ITT) principle
(e.g., group status is determined by randomization at base-
line). A p-value < 0.05 will be used to indicate statistical sig-
nificance for all analyses.
The primary aim analyses will compare the ASAP and
DEUCC group change in log WMFT time score and suc-
cess rate from the SIS hand domain and the full SIS. For
the primary hypothesis, change in WMFT time score at
1 year, an independent sample t-test will be used to com-
pare the mean change in log-transformed WMFT time
score, and analysis of covariance (ANCOVA) will be used
to adjust for a priori covariates (site, initial motor impair-
ment, stroke duration to randomization, baseline log time
score) and any baseline variables that were imbalanced be-
tween ASAP and DEUCC. For missing data from loss to
follow-up or missed evaluations at 12-months, multiple im-
putation using all available evaluation data will be utilized.
Adjusted least-square means and the associated 95% confi-
dence interval will be presented as well as p-value, and ef-
fect sizes will be computed to aid in interpretation of
results.
For the secondary hypothesis, the success rate of the SIS
hand domain will be calculated as the percent of subjects in
the ASAP and DEUCC groups that achieved at least a 25-
point increase in normalized SIS hand function at 1 year
post randomization compared to baseline. Logistic regres-
sion will be used to compare these rates between groups,
while adjusting for covariates. Since there are no prior data
or biological evidence suggesting that ASAP will have a dif-
ferential effect on one subgroup compared to DEUCC in
the targeted population, we are not planning any a priori
interactions between treatment and any of the covariates in
the main analysis. However, we will perform exploratory
data analysis to examine these possible interactions and
generate hypotheses for future studies.
The analytic approach to the secondary aims will follow
that described for the primary aims above, with the excep-
tion of comparing differences between groups receiving
30 hours of treatment (ASAP and DEUCC) to UCC. For
other secondary outcomes, baseline to 1-yr change will be
compared between ASAP and DEUCC groups and ASAP
and UCC groups using analysis of covariance or logistic re-
gression models (see Additional file 1). In addition, a com-
posite physical domain, which includes strength, hand
function, ADL/IADL, and mobility, will be created and
compared in a similar way. Bonferroni adjustments will be
made of the critical p-value for these secondary analyses, as
there are two comparisons: ASAP to UCC and DEUCC to
UCC; a p-value < 0.025 will be used to indicate significance.
Interim analysis plan
A single interim data analysis of Specific Aim 1 (ASAP vs
DEUCC) for only the primary outcome, WMFT time, will
be performed when approximately 33% of the participants
have completed the 1-year evaluation. The O’Brien-
Fleming group sequential method [92] will be used with
the significance level defined as 0.005 at the interim analysis
to maintain the overall type I error of 0.05. The advantage
of the O’Brien Fleming method is: 1) it is conservative for
significance at the interim analysis point, and 2) it main-
tains the conventional p-value in the final analysis. Group
assignment will remain blinded with codes X and Y repre-
senting either ASAP or DEUCC groups to avoid revealing
treatment assignment. Only the primary outcome for the
primary aim (log WMFT mean time) will be analyzed as
described above. If the test of success rate in WMFT time
at the interim analysis point reaches a p-value less than
these critical p-values, the DSMB will decide whether ana-
lysis of secondary outcomes is necessary to provide add-
itional support of the results. If deemed necessary by the
DSMB, conditional power will be computed to make a re-
assessment of the power at the end of the trial.
Missing data
The DMAC conducts weekly checks for all expected mea-
surements in the database. Missing data must be identified
by the cause of missing data, (e.g. participant not able to
complete the measurement or evaluator error, forgot to rec-
ord the data). Detailed reasons for missing data are
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recorded in a comment box under each measurement. This
missing data form/point control procedure will enable fu-
ture analysis for missing data patterns (e.g., systematic or
random), and thus, support decision making for final data
analysis.
Adverse event monitoring and reporting
Adverse events (AE) are monitored closely and supported
by the ICARE database that sends auto-alerts to team
members, the NINDS clinical trial liaison to the DSMB and
the Medical Safety Monitor (MSM). AEs include new
events not present prior to enrollment in the study or
events that were present during the pre-enrollment period
but have increased in severity. All adverse events are
reported in terms of three factors: 1) Serious or Non-ser-
ious, 2) Expected or Unexpected, 3) Related or Unrelated.
These discrete categories and each characteristic of the
event are evaluated independently of the others. An AE is
considered serious (SAE) if it involves death, a life-
threatening event, inpatient hospitalization, or persistent
and/or significant disability/incapacity that lasts more than
48 hours, limits activities of daily living, and (in the opinion
of the investigators) represents significant hazard or poten-
tial serious harm to the participant or others. Non-serious
events are minor events that do not seriously limit a partici-
pant’s activities of daily living or present a potential risk to
the participant or others. Expected serious events include:
recurrent stroke or TIA; myocardial infarction or acute cor-
onary syndrome; new onset of cardiac arrhythmia; fracture;
pulmonary embolism; inpatient hospitalization or ER visit
greater than 23 hours; and death. Expected non-serious
events include: fall with no fracture; dyspnea; open sore or
cuts; muscle soreness or pain that persists for more than
48 hours; shoulder pain that limits study participation; ex-
cessive blood pressure responses that require treatment dis-
continuation for the day; dizziness/fainting; deep vein
thrombosis, without pulmonary embolus, and depression
requiring mental health intervention. A related adverse
event reflects a realistic chance of a causal relationship be-
tween participation in the study and the adverse event as
suggested by an event that follows within a reasonable time
after research procedures (i.e., 24 hours), follows a pattern
consistent with study procedures, improves when study
procedures have stopped and/or reappears when the proce-
dures in question are repeated. An adverse event that does
not reflect a realistic chance of a causal relationship be-
tween participation in the study and the adverse event, as
described above for a related adverse event, is an unrelated
adverse event.
Adverse events reporting procedures
The adverse event reporting system was developed with
NINDS guidance, and has a pre-planned, automatic work-
flow that triggers instant electronic communication. A site
team member completes the online “Adverse Event Initial
Report Form” within 24 hours of knowledge of an event
and in compliance with all local IRB reporting procedures.
This initiates the report process. The initial report is in-
stantly added to the ICARE database and triggers an imme-
diate, automatic notification to the study PIs, project
manager, originating site’s physician investigator and clinical
site coordinator, and DMAC members. The site physician
investigator is responsible to obtain all necessary facts to
verify and adequately describe the event, determine serious-
ness, determine the appropriate course of action and report
these items via the ICARE “Adverse Event Confirmation
Form” to the database within 72 hours after the initial re-
port submission. If the AE is confirmed as serious, an im-
mediate, automatically triggered email notification with a
narrative of the SAE is sent to the study PI’s, project man-
ager, originating site’s physician investigator and clinical site
coordinator, MSM and the DSMB liaison. The MSM will
review the SAE narrative and adjudicate study-relatedness
and expectedness within 5 days (120 hours) of the auto-
mated email notification of an SAE. If data are not entered
within the first 96 hours, an automated courtesy reminder
is sent to the MSM. A detailed AE report is generated
weekly and available to all study personnel. An AE sum-
mary report is generated and reviewed quarterly by the
Data Safety and Monitoring Board (DSMB) and the USC
IRB. Each site reports to its respective IRB in accordance
with its policies and procedures. All AE reports, and
amendments to them, are recorded and monitored by the
DMAC.
Data management and quality
Data management
The DMAC consists of the director, who is the unblinded
statistician and who is responsible for managing the DMAC
and acting as liaison to the DSMB for data-related matters,
including preparation of reports and analyses (interim and
primary outcomes). The other DMAC members are staff
from USC’s Statistical Consultation and Research Center
and include a co-director in charge of database develop-
ment and management, a programmer, data manager and
two research assistants. Additionally, a blinded statistician
serves on the executive committee and is able to answer
statistical questions that arise without danger of breaking
the blind of the study.
Quality control procedures
MicrosoftW SQL Server 2000 Edition is utilized for the se-
cure database. This database is configured to utilize trans-
action logging for auditing and recovery purposes. All data
entry/retrieval travels over the Hypertext Transfer Protocol
Secure (HTTPS) layer. Backups are conducted daily,
weekly, monthly and quarterly. The backup files are stored
in a backup server at a secure separate location. The
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WMFT video files are stored in a multimedia server and
streamed to the data entry system with the corresponding
accession number, which provides blinding to site and
evaluation time point.
Users are issued individual usernames and passwords to
gain access to the secure web-based data entry system.
Since ICARE is a multisite study, each site has access only
to its site- specific data records. Within each site, only
designated personnel can enter and modify data. The
blinded evaluators are prohibited from accessing any treat-
ment related information in the database, including
randomization assignment.
All clinical report forms (CRF) are barcoded to prevent
ID error. Sites are required to scan and submit the original
CRFs for all key outcome measurements to the DMAC for
data entry quality checking. Quarterly, the DMAC performs
data quality checking (QC) on 100% of primary outcome
data (WMFTand SIS).
Study organization and management
ICARE is conducted by an experienced multidisciplinary
research team, and is managed through a series of commit-
tees. This trial uses a multiple-PI management plan with
the following designations: PI#1 is Carolee Winstein, PhD,
PT, FAPTA, PI#2 is Alexander Dromerick, MD, and PI#3 is
Steven Wolf, PhD, PT, FAPTA. PI#1 chairs the executive
committee (EC), the small study leadership group that
guides ICARE implementation and operations. This com-
mittee is composed of the PIs, study project manager (PM),
blinded statistician and DMAC consultant, and NINDS sci-
entific program director. It meets weekly by conference call.
The EC is responsible for the general design and conduct
of the study, protection of human research subjects, review
of study progress and data collection, changes in study pro-
cedures, allocation of resources, and communication with
the DSMB and NINDS. All dissemination ideas are vetted
through the Executive Committee. When necessary the EC
invites the DMAC Director, to participate in the meeting
especially for preparation and discussion of DSMB reports.
PI#1, 2 and 3 lead implementation of the scientific agenda
and specific aims and ensure that systems are in place to
guarantee responsible management of the RCT.
PI#1 serves as the primary contact PI, assumes fiscal and
administrative responsibility for the trial and plays a lead
role in the training and standardization of the ASAP thera-
pists, including development of multi-media training tools.
The DMAC, in consultation with PI#1 and the PM, develop
and provide all reports to the DMSB and the NIH in accord
with a pre-established time line for reporting.
PI#2 is responsible for all medical and neurologic
issues that arise during participant screening, therapy,
and follow-up. As study medical director, he is responsible
for identification of stroke diagnosis and characterization
and inclusion/exclusion criteria related to medical and
diagnostic features of study participants. This responsibil-
ity includes review of brain images and response to diag-
nostic queries, review of adverse events and
communication with the DSMB liaison when appropriate.
PI#2 and 3 are responsible for managing their subcon-
tract and providing leadership at their respective Center
including all clinical affiliates (PI#2 NRH; PI#3 Emory) to
assure that each center investigative and clinical team im-
plement the trial in accord with all policies and procedures
detailed in the MOP. Additional leadership at each geo-
graphic center is provided by a designated center coordin-
ator. Each site is led by a Clinical Site Coordinator (CSC)
and Site Physician Investigator (SPI). For each of the roles
of CSC, SPI, intervention therapist and blinded evaluator,
there are trained, standardized back-up personnel. An
experienced clinician oversees training and certification for
the WMFT, with consultation from the tool’s developer
(PI#3) and the PM. All PIs, the PM and DMAC Director
share in monitoring study progress, including: recruitment,
adherence, retention, safety and missing data. The Execu-
tive Committee guides the management of issues identified
study-wide; whereas PI#1, the PM and, when necessary, the
DMAC Director, manage site-specific issues. Both groups
collaborate with the site teams to implement solutions and
monitor effectiveness. PI#1, the PM and DMAC Director
visit each site annually to monitor data quality, process and
compliance and consult regarding site-specific issues. PI#1
and the PM coordinate with the DMAC on website and in-
formatics work, to issue weekly progress reports to the
investigative and clinical teams, and to maintain and update
the MOP and CRFs as needed.
The Data Safety and Monitoring Board (DSMB) is
appointed by the NINDS to ensure highest quality and eth-
ical study execution and consists of a stroke neurologist, a
physical therapist, a rehabilitation neurologist, a biostatisti-
cian, and an NINDS DSMB liaison. The DSMB evaluates a
full study report, prepared by the DMAC Director and
Project Manager, biannually. This report provides a sum-
mary of study activities, issues and progress since the last
report in narrative form followed by data tables and figures,
which include grouped data sets, blinded for treatment allo-
cation. As an appendix to the report, each site prepares a
site-specific narrative including proactive strategies for any
areas of concern. Both the main report and the site-specific
reports address the primary issues of: participant accrual,
execution of intervention adherence (ASAP & DEUCC
only), retention, safety and data quality, including missing
data, protocol adherence, and safety. An abbreviated report
is evaluated by the DSMB during the interceding quarters.
The DSMB monitors serious adverse events and reviews
cumulative adverse event data quarterly to ensure study
safety. These data are also grouped, but blinded for treat-
ment allocation. The DMAC Director prepares unblinded
reports and analyses if requested by the DSMB. The DSMB
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meets biannually with the Executive Committee, DMAC
Director, and MSM, alternating between tele-conference
and in person meetings per annum. Additional meetings
may be scheduled at the discretion of the DSMB or
NINDS.
An independent Medical Safety Monitor (MSM) is
chosen by the NINDS staff and the Executive Committee.
This rehabilitation physician is responsible for timely review
and adjudication of all serious adverse events and for
reviewing summary reports of all adverse events on a regu-
lar basis. The MSM attends the annual DSMB meetings as
well as the quarterly phone meetings.
The Clinical Site Coordinator (CSC) Committee consists
of the Project Manager, and seven Clinical Site Coordina-
tors; a DMAC member, PI#1 and other study personnel
join as needed. This committee is responsible for collabora-
tive training and problem-solving; recruitment, protocol
implementation; data entry; resolution of site differences
and assurance of trial consistency. This committee meets
twice monthly.
The Clinical Research Committee is comprised of PI’s #1,
2 and 3, the PM, the three Clinical Center Coordinators
(CCC), the DMAC Director and the psychosocial consult-
ant. It meets monthly and is responsible for strategic plan-
ning, protocol development and implementation, CRF
development and identification and development of sec-
ondary research questions.
The Physician Investigator Committee consists of the
seven physician investigators across the clinical sites, the
CCC, the PM, and PI#1. This group addresses relevant
medical issues, assists in study recruitment, develops strat-
egies to enhance recruitment, and facilitates acquisition of
neuroimaging studies for secondary analyses. This commit-
tee will generate topics for secondary publications relevant
to ICARE and the medical management of sub-acute
stroke.
A Blinded Evaluator Committee consists of all blinded
evaluators across the three centers, the CCC, PM and
the WMFT reviewer. The BE committee focuses on
standardization and execution of measurement, assur-
ance of data completeness, participant safety, and pre-
vention and documentation of unblinding.
The Publications Committee is comprised of the three
PIs and the DMAC Director. It will establish a policy and
oversee study publications to ensure that they are ethical
and of high scientific quality. The committee will mediate
when there is disagreement about an issue related to the
form or scope of the publication and related issues includ-
ing authorship. While generally not responsible for deci-
sions regarding content, the committee may intervene in
cases where a manuscript may include claims or interpreta-
tions that are not supported by the data. All publications
emergent from the ICARE database will be vetted through
the publications committee.
Discussion
ICARE will contribute significantly to the practice of out-
patient stroke rehabilitation, our knowledge of arm and
hand recovery and to our understanding of how to conduct
large-scale, multi-site clinical trials of complex rehabilita-
tion interventions. There will be several unique contribu-
tions to the practice of arm and hand therapy after stroke.
First, ICARE tests the value of a structured, principle-based
and standardized arm and hand rehabilitation program in a
sufficient number of participants of modest variety to pro-
vide a reasonable basis for confident inference to the clin-
ical practice setting. Second, the primary endpoint, one
year after randomization, assesses the durability of any
benefit at a time sufficiently removed from the therapy to
reflect behavioral learning (i.e., patient-centered control) ra-
ther than a short-term performance boost that may be ther-
apist and/or therapy dependent.
The value of ASAP will be tested against an equivalent
dose (30 hours) of usual and customary therapy delivered
by an Occupational Therapist that provides a plausible con-
trol for the number of outpatient visits during a time of
dwindling rehabilitation services. The trial will also help to
determine the current state of outpatient therapy services
for post-stroke arm and hand rehabilitation as there is a
monitoring-only usual and customary care comparison
group for which the prescribed dose is monitored. Finally,
the trial will examine the impact of treatment on a suffi-
cient number of ancillary assessments that cut across the
ICF domains to make its outcomes easily comparable with
those of other trials.
Current study status
Enrolling participants. We expect to close enrollment
by early 2013. An interim analysis was completed in
November, 2011. The DSMB recommended continu-
ation of recruitment.
Additional file
Additional file 1: Outcome Assessments listed in Table 3
categorized using the International Classification of Functioning
and Disability Framework.
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